Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Medical - Instruments & Supplies

Healthcare
$28.29 -0.37%

-$0.07 today

Market cap
$1.69B
Beta
0.83
P/E (TTM)
-6.9
EPS (TTM)
-$2.74
52W Low $13.25High $30.00

Volume 0.44M

Average 0.33M

KMTS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Kestra Medical Technologies, Ltd.NASDAQ: KMTS

Research & Development · Q3 FY2026 · quarter ended Jan 2026

Research & development growth accelerates

Q3 FY2026 research & development of $4.97M rose 48.3% year over year, ahead of the +36.6% change in trailing-twelve-month research & development. Sequentially, it rose 1.9% from the prior quarter.

Context

  • Research & development amounted to 26.2% of revenue in FY2025, down 29.5 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +48.3% holds above the trailing-twelve-month pace of +36.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
$4.97M+1.9% QoQ
Last fiscal yearApr 2025
$15.65M+1.0% YoY
LTMJan 2026
$19.24M+36.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.3%——
1 year+1.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
15.65M USD
Year-over-year change
+1.0%
5-year CAGR
-7.2%

Research & Development vs competitors

How KMTS compares with its peers on the latest reported figures

  • KMTS's LTM Jan 2026 research & development of $19.24M is the 2nd highest of the 3 companies compared; the peer median is $47.27M.
  • Its year-over-year change of +36.6% is the highest of 3, against a peer median of +5.2%.
  • Research & development amounts to 23.0% of revenue for KMTS, versus a peer median of 14.8%.
KMTS Competitors Peer median
Research & Development for KMTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRTCiRhythm Technologies, Inc.LTM Sep 2026$82.85M -0.1%+22.0%9.7%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$19.24M +36.6%—23.0%
CVRXCVRx, Inc.LTM Mar 2026$11.7M +10.5%+3.8%19.8%
Peer median (excluding KMTS) $47.27M+5.2%+12.9%14.8%

Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2020
Apr 2020
FY2021
Apr 2021
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue007.63M27.81M59.82M
Cost of Revenue0018.28M27.45M35.61M
Gross Profit00(10.65M)362K24.21M
Gross Margin——-139.6%1.3%40.5%
Research & Development22.8M18.81M15.76M15.49M15.65M
Selling, General & Admin6.52M13.9M54.01M69.94M114.94M
Operating Expenses29.32M32.71M69.77M85.43M130.59M
Depreciation & Amortization478K420K4.86M11.56M7.97M
EBITDA(28.84M)(32.33M)(73.74M)(76.31M)(97.98M)
EBITDA Margin——-966.4%-274.3%-163.8%
Operating Income(29.32M)(32.71M)(80.42M)(85.06M)(106.38M)
Operating Margin——-1054.0%-305.8%-177.8%
Interest Income00003.2M
Interest Expense01.17M5.63M6.23M7.73M
Other Income / Expenses0(1.21M)(3.8M)(9.03M)(7.3M)
Income Before Tax(29.32M)(33.91M)(84.22M)(94.1M)(113.68M)
Pre-Tax Margin——-1103.8%-338.3%-190.1%
Income Tax Expense148K187K15K24K135K
Net Income(29.47M)(34.1M)(84.24M)(94.12M)(113.81M)
Net Margin——-1104.0%-338.4%-190.3%
EPS (Basic)(0.59)(0.69)(1.75)(2.04)(5.13)
EPS (Diluted)(0.59)(0.69)(1.75)(2.04)(5.13)
Weighted Avg Shares49.53M49.53M49.53M49.53M49.53M
Weighted Avg Shares (Diluted)49.53M49.53M49.53M49.53M49.53M

Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Intrinsic Alpha fair value

Locked

Current Price

$28.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.